Karnataka Plans Tougher Action Against Fake Medicine Sellers

The Karnataka government is considering stronger legal action against those allegedly involved in the sale and distribution of fake medicines, with officials examining whether serious criminal charges could be pursued in cases where public health was knowingly put at risk.

The development comes as an investigation into spurious medicines continues across the state. Authorities are looking beyond individual sellers and are attempting to trace how the medicines entered the supply chain, who handled them and where the money involved in the alleged operation moved.

A Special Investigation Team is examining the wider network. Recent reporting said the investigation had identified spurious medicines worth around Rs 12 crore that were allegedly supplied to hospitals and clinics in Bengaluru and other parts of Karnataka since February 2025.

The investigation is also expected to involve coordination between agencies dealing with policing, drug regulation and taxation. Such coordination can help investigators examine both the movement of medicines and the financial transactions connected with an alleged illegal supply chain.

The Karnataka Food and Drug Administration has already taken action against several businesses in connection with the fake medicine investigation. Recent reports said 16 drug licences were cancelled and eight others were suspended following action linked to the distribution of spurious medicines.

The authorities have also been examining allegations involving fake labels, questionable packaging and non functional QR codes. In one operation, officials reportedly seized counterfeit medicines along with machinery and printing material from a premises in Bidadi.

The proposed tougher legal approach reflects the seriousness with which the state is treating the alleged supply of medicines that do not meet required quality standards. However, whether specific individuals face particular criminal charges will depend on the evidence gathered during the investigation and the applicable law.

Alongside the Karnataka investigation, the Central Drugs Standard Control Organisation has issued a separate advisory concerning the use of painkillers and antibiotics. The regulator published a circular on September 22 warning about the risks associated with indiscriminate use of these medicines and their connection with chronic kidney disease.

The advisory asks doctors to use antibiotics and non steroidal anti inflammatory drugs only when clinically indicated and to consider factors such as the patients age, existing medical conditions, other medicines and relevant risk factors. The medicines should be prescribed at the appropriate dose and for the appropriate duration under medical supervision.

The message also extends to pharmacies and retailers. The regulator has said pharmacists and retailers should not encourage or facilitate self medication with antibiotics or prescription only painkillers. The public has similarly been advised against taking antibiotics without appropriate medical advice.

The warning is important because antibiotics do not work against most uncomplicated viral infections, while unnecessary or repeated use can contribute to antimicrobial resistance. Certain painkillers can also create health risks when used indiscriminately or for prolonged periods, particularly among people who already have factors that increase the risk of kidney problems.

For doctors, the latest advisory reinforces the need to consider the individual patient before prescribing these medicines. A medicine that may be appropriate in one situation may not be suitable for another person because of age, existing conditions or interactions with other medicines.

For pharmacies, prescription compliance remains an important part of responsible medicine distribution. The latest regulatory guidance places emphasis on preventing self medication and ensuring that prescription medicines are supplied in accordance with the applicable rules.

The developments in Karnataka therefore involve two connected but separate concerns. The state investigation is focused on alleged fake medicine distribution and the people or businesses behind the supply network, while the central advisory addresses the safer and more responsible use of genuine medicines.

The fake medicine investigation is expected to continue as officials examine the full supply chain. More action could follow if investigators establish the involvement of additional businesses or individuals.

For patients, the developments are a reminder to obtain medicines through legitimate channels and to follow prescriptions carefully. Antibiotics and strong pain medicines should not be taken simply because they were used successfully for an earlier illness.

As Karnataka authorities continue investigating the alleged fake medicine network, the focus is likely to remain on identifying those responsible, tracing the distribution chain and preventing potentially unsafe products from reaching patients.